8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Prognostic significance of laterality in renal cell carcinoma: A population‐based study from the surveillance, epidemiology, and end results (SEER) database

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Various prognostic characteristics have been established in the renal cell carcinoma (RCC). However, the impact of tumor laterality is unknown. The objective of the current study was to explore the predictive and prognostic impact of tumor laterality of RCC after surgery.

          Methods

          This investigation was a population‐based retrospective cohort study of patients with RCC from the surveillance, epidemiology, and end results (SEER) database in the USA. All patients received surgical treatment between January 2010 and December 2014. Cancer‐specific survival (CSS) measured from the time of surgery.

          Results

          This study identified 41 138 surgically treated RCC patients: Of these patients, 50.6% had right‐sided RCC, 59.5% were younger than 65 years of age, 63.8% were male, and 81.0% were Caucasian. The stage distribution was 67.0% (I), 9.5% (II), 17.1% (III), and 6.4% (IV). Patients with right‐sided RCC were more likely to have favorable clinicopathological features compared with patients with left‐sided RCC. In adjusted analyses, patients with right‐sided RCC showed significantly better CSS than those with left‐sided RCC within different subgroups including tumor size ≥10 cm ( P = .004), age <65 years ( P = .002), male gender ( P = .001), Caucasian race ( P = .001), clear cell carcinoma type ( P = .024), and radical nephrectomy ( P = 0.008). Moreover, in the subgroup of tumor size ≥10 cm, right‐sided cancer was an independent predictor of CSS ( P = .022).

          Conclusion

          Right‐sided RCC is associated with more early‐stage, low‐grade disease and shows better CSS than left‐sided RCC. Moreover, laterality remained as an independent prognostic factor for cancer‐specific survival in subgroup of tumor size ≥10 cm RCC.

          Abstract

          Renal cell laterality could be a prognostic factor for cancer‐specific survival in subgroup of tumor size ≥10 cm RCC. Right‐sided RCC is associated with more early‐stage, low‐grade disease and shows better CSS than left‐sided RCC.

          Related collections

          Most cited references12

          • Record: found
          • Abstract: found
          • Article: not found

          Prognostic factors and predictive models in renal cell carcinoma: a contemporary review.

          The natural history of renal cell carcinoma (RCC) is highly unpredictable. Small renal masses may be accompanied by metastatic disease. Conversely, patients with locally advanced disease may enjoy long-term disease-free survival. To review the status of prognostic factors in RCC. A literature review was performed using the PubMed, MEDLINE, and Cochrane databases for articles published as of February 15, 2010. Electronic articles published ahead of print were also considered. Search was limited to the English language. Search was conducted using the following keywords: renal cell carcinoma, molecular, tissue, markers, blood, urine, progression, prognosis, risk factor, and survival. Studies were selected according to the relevance of the study, the number of patients included, originality, actuality, and clinical applicability of the results. Four areas of prediction were examined: (1) new RCC diagnostics, (2) RCC grade and stage at diagnosis, (3) disease progression, and (4) disease-specific mortality. All identified reports represented either case series or controlled studies. Although a large number of markers were identified, only a few were validated. Several prognostic factors were integrated in predictive or prognostic models. Several prognostic factors can help discriminate between favourable and unfavourable RCC phenotypes. Of those, several clinical, pathologic, and biologic markers have been tested and validated, and they are used in predictive and prognostic models. Nonetheless, the search continues, especially for informative markers predicting the response to targeted therapies. Crown Copyright © 2011. Published by Elsevier B.V. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            The surveillance, epidemiology, and end results program: a national resource.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Landmarks in the diagnosis and treatment of renal cell carcinoma.

              The most common renal cancer is renal cell carcinoma (RCC), which arises from the renal parenchyma. The global incidence of RCC has increased over the past two decades by 2% per year. RCC is the most lethal of the common urological cancers: despite diagnostic advances, 20-30% of patients present with metastatic disease. A clearer understanding of the genetic basis of RCC has led to immune-based and targeted treatments for this chemoresistant cancer. Despite promising results in advanced disease, overall response rates and durable complete responses are rare. Surgery remains the main treatment modality, especially for organ-confined disease, with a selective role in advanced and metastatic disease. Smaller tumours are increasingly managed with biopsy, minimally invasive interventions and surveillance. The future promises multimodal, integrated and personalized care, with further understanding of the disease leading to new treatment options.
                Bookmark

                Author and article information

                Contributors
                junxingchen@hotmail.com
                cwu2@partners.org
                Journal
                Cancer Med
                Cancer Med
                10.1002/(ISSN)2045-7634
                CAM4
                Cancer Medicine
                John Wiley and Sons Inc. (Hoboken )
                2045-7634
                12 August 2019
                September 2019
                : 8
                : 12 ( doiID: 10.1002/cam4.v8.12 )
                : 5629-5637
                Affiliations
                [ 1 ] Department of Urology, Sun Yat‐Sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou China
                [ 2 ] Department of Urology and Pathology Massachusetts General Hospital Harvard Medical School Boston MA USA
                [ 3 ] Glickman Urological and Kidney Institute, Cleveland Clinic Cleveland OH USA
                [ 4 ] Department of Urology The First Affiliated Hospital Sun Yat‐Sen University Guangzhou China
                Author notes
                [*] [* ] Correspondence

                Junxing Chen, Department of Urology, The First Affiliated Hospital, Sun Yat‐Sen University, No. 58 Zhong Shan 2nd Road, Guangzhou 510080, China.

                Email: junxingchen@ 123456hotmail.com

                Chin‐Lee Wu, Department of Pathology and Urology, Massachusetts General Hospital, Warren Building 225, 55 Fruit Street Boston, MA 02114.

                Email: cwu2@ 123456partners.org

                Author information
                https://orcid.org/0000-0001-7953-8775
                https://orcid.org/0000-0001-5424-7066
                https://orcid.org/0000-0002-0444-0068
                Article
                CAM42484
                10.1002/cam4.2484
                6745836
                31407495
                7bdd9024-12e2-4dab-9818-99b74209d537
                © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 11 April 2019
                : 19 July 2019
                : 29 July 2019
                Page count
                Figures: 1, Tables: 4, Pages: 9, Words: 6541
                Categories
                Original Research
                Clinical Cancer Research
                Original Research
                Custom metadata
                2.0
                September 2019
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.6.9 mode:remove_FC converted:16.09.2019

                Oncology & Radiotherapy
                laterality,nephrectomy,prognosis,renal cell carcinoma,seer
                Oncology & Radiotherapy
                laterality, nephrectomy, prognosis, renal cell carcinoma, seer

                Comments

                Comment on this article